Advertisement

Topics

PubMed Journals Articles About "Pevion Biotech AG" RSS

20:20 EDT 18th March 2019 | BioPortfolio

Pevion Biotech AG PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Pevion Biotech AG articles that have been published worldwide.

More Information about "Pevion Biotech AG" on BioPortfolio

We have published hundreds of Pevion Biotech AG news stories on BioPortfolio along with dozens of Pevion Biotech AG Clinical Trials and PubMed Articles about Pevion Biotech AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pevion Biotech AG Companies in our database. You can also find out about relevant Pevion Biotech AG Drugs and Medications on this site too.

Showing "Pevion Biotech" PubMed Articles, all 23

Third-quarter biotech job picture.


New Nonprofit Biotech From Bill and Melinda Gates.

Biotech leaders call for free press.


US law threatens flow of foreign capital to biotech sector.

Genetic data sharing: a new type of capital.

Over the last three decades, various biotech companies, mostly in North America, have become experts in the production, processing and analysis of large volumes of genetic data. They have surpassed the performance of traditional academic platforms, by appropriating a new economic model: the two-sided market. Thus, by applying web 2.0 ideas, these biotech companies have made it possible for millions of users to produce and "share" data including genetic data, with each other and with third parties through a...

Detection of Transgenic Proteins by Immunoassays.

Rapid development and global cultivation of genetically modified (GM) crops necessitated the use of analytical tools that detect GM crops throughout the product life cycle. Antibody-based immunoassays such as enzyme-linked immunosorbent assays (ELISA) are instrumental in detecting protein expression in transgenic plants. These analytical tools are used throughout development, regulatory registration, commercialization, and stewardship of biotech products. Here we describe the Cry1F ELISA analytical method p...

The Complexity of Compliance in Sample Management: A Review of Key Issues Impacting Small-Molecule and Biological Sample Management in Early Drug Discovery.

The discovery of new medicines has become increasingly more challenging and requires significant collaboration between pharma, biotech, academia, and technology to be successful. These partnerships necessitate the streamlined exchange of samples while adhering to the increasingly complex set of legal and proprietary restrictions, government legislation, and ethical considerations associated with samples. There is a significant volume of literature published on clinical sample compliance but little describin...

Multiscale heterogeneity in filamentous microbes.

Microbial cells within clonal populations can display different morphologies or carry out different tasks. This heterogeneity is beneficial at the population level and allows microbes to spread risk or separate incompatible activities. Heterogeneity is also evident in filamentous bacteria and fungi, which form mycelial networks consisting of interconnected hyphae. Here, heterogeneity is observed between clonal mycelial particles, between different zones of colonies, between adjacent hyphae and even between ...

China Medicinal Biotech Association, Chinese Association of Digestive Disease and Chinese Society of Gastroenterology Consensus on standard biobanking of the gut microbiota.

Biobanks are collections of various biological samples and their related information. These samples include organs, tissues, cells, blood, body fluids, secretions, excretions and biological macromolecular derivatives from healthy or diseased individuals that are collected, processed, stored and utilized under standard procedures. Sample-related information consists of clinical information, test results, pathology, imaging, treatment, follow-up visits and informed patient consent as well as quality control, ...

Programmable Molecular Scissors: Applications of a New Tool for Genome Editing in Biotech.

Targeted genome editing is an advanced technique that enables precise modification of the nucleic acid sequences in a genome. Genome editing is typically performed using tools, such as molecular scissors, to cut a defined location in a specific gene. Genome editing has impacted various fields of biotechnology, such as agriculture; biopharmaceutical production; studies on the structure, regulation, and function of the genome; and the creation of transgenic organisms and cell lines. Although genome editing is...

An industry update: the latest developments in therapeutic delivery covering September 2018.

The present industry update covers the period 1-30 September 2018, with information sourced from company press releases, regulatory and patent agencies as well as scientific literature. Various technologies using reformulations of know drugs with nanoparticles, hydrogels, aerosols, etc. emerged in new financing rounds (BioTime; CA, USA, SiSaf; Guildford, UK, Cassion Biotech; TX, USA), intellectual property protection (TFF Pharmaceuticals; TX, USA), repackaging (Leiters; CA, USA) and reformulation (Virpax Ph...

Creating Targeted Gene Knockouts in Brassica oleracea Using CRISPR/Cas9.

While public and political views on genetic modification (inserting "foreign" genes to elicit new traits) have resulted in limited exploitation of the technology in some parts of the world, the new era of genome editing (to edit existing genes to gain new traits/genetic variation) has the potential to change the biotech landscape. Genome editing offers a faster and simpler approach to gene knockout in both single and multiple genetic locations, within a single or small number of generations, in a way that h...

Interaction of substrate-mimicking peptides with the AAA+ ATPase ClpB from Escherichia coli.

A molecular chaperone ClpB disaggregates and reactivates aggregated proteins in cooperation with DnaK, DnaJ, and GrpE. Within a cellular environment, ClpB must distinguish between properly folded and aggregated proteins by recognizing specific physical and/or chemical surface properties of the aggregates. However, the molecular mechanism of substrate binding to ClpB is poorly understood. We hypothesized that ClpB recognizes those polypeptide segments that promote protein aggregation because they are likely ...

CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.

Clustered regularly interspaced short palindromic repeats/CRISPR associated nuclease9 (CRISPR/Cas9) technology, an acquired immune system in bacteria and archaea, has provided a new tool for accurately genome editing. Using only a single nuclease protein in complex with 2 short RNA as a site-specific endonuclease made it a simple and flexible genome editing tool to target nearly any genomic locus. Due to recent developments in therapeutic engineered T cell and effective responses of CD19-directed chimeric a...

Bacillus thuringiensis Cry1A toxins exert toxicity by multiple pathways in insects.

Adoption of biotech crops engineered to express insecticidal toxins from Bacillus thuringiensis (Bt) has revolutionized insect pest control in agriculture. For continuing effective application and development of the environmentally friendly Bt biotechnology, it is fundamental to understand pathways of toxicity of Bt toxins in insects. In this study, mutations were introduced in the midgut cadherin gene in the cabbage looper, Trichoplusia ni, by CRISPR/Cas9 mutagenesis. T. ni strains with mutations in the ge...

Implications of CRISPR-Based Germline Engineering for Cancer Survivors.

Cancer survivors can carry germline mutations that will be transmitted to their progeny. Today, many of these mutations have been identified and can be tracked. With the recent development of genome-editing technologies and CRISPR (clustered regularly interspaced short palindromic repeats), the possibility of genetically modifying the human germline-gametes and embryos-has never been closer. This perspective has sparked a controversy within the scientific community with reactions ranging from calls for a ba...

Falsely high HbA value due to a novel α1-globin gene mutation: Hb shantou α127(H10)Lys > Glu; HBA1: c.382 A > G.

Hemoglobin A (HbA) is a widely utilized biomarker for the diagnosis and management of diabetes mellitus. Here, we describe an α1-globin chain hemoglobin variant and investigate its effect on HbA measurement. A 26-year-old pregnant woman was suspected to harbor a hemoglobin variant following HbA measurement during a routine prenatal examination using D10 (Bio-Rad). An oral glucose tolerance test (OGTT) was performed using an AU5800 clinical chemistry system (Beckman Coulter). HbA was reanalyzed using VII-T ...

RABiT-II: A Fully-Automated Micronucleus Assay System with Shortened Time to Result.

In this work, we describe a fully automated cytokinesis-block micronucleus (CBMN) assay with a significantly shortened time to result, motivated by the need for rapid high-throughput biodosimetric estimation of radiation doses from small-volume human blood samples. The Rapid Automated Biodosimetry Tool (RABiT-II) currently consists of two commercial automated systems: a PerkinElmer cell::explorer Workstation and a GE Healthcare IN Cell Analyzer 2000 Imager. Blood samples (30 μl) from eight healthy voluntee...

New therapies for human cytomegalovirus infections.

The recent approval of letermovir marks a new era of therapy for human cytomegalovirus (HCMV) infections, particularly for the prevention of HCMV disease in hematopoietic stem cell transplant recipients. For almost 30 years ganciclovir has been the therapy of choice for these infections and by today's standards this drug exhibits only modest antiviral activity that is often insufficient to completely suppress viral replication, and drives the selection of drug-resistant variants that continue to replicate a...

Structural Dynamics of PET-degrading Cutinase-like Enzyme from Saccharomonospora viridis AHK190 in Substrate-bound States Elucidates Ca Driven Catalytic Cycle.

A cutinase-type polyesterase from Saccharomonospora viridis AHK190 (Cut190) has been shown to degrade the inner block of polyethylene terephthalate. A unique feature of Cut190 is that its function and stability are regulated by Ca binding. Our previous crystal structural analysis of Cut190S226P has shown that one Ca ion binds to the enzyme, which induces large conformational changes in several loop regions to stabilize an open conformation ( Appl. Microbiol. Biotech. 2015, 99, 4297). In this study, to analy...

Ensuring Product Quality, Consistency and Patient Supply over Time for a Large-Volume Biologic: Experience with Remicade.

Biologics are produced from living organisms in complex, multi-stage manufacturing processes and contain inherent variability, which must be understood and controlled during manufacturing to avoid unexpected changes in key quality attributes that may contribute to clinically meaningful differences. The process must also meet large commercial demand, while simultaneously being able to accommodate change without sacrificing product consistency. The four key components of successful biologics manufacturing are...

A methodology study on chemical and molecular structure imaging in modified forage leaf tissue with cutting-edge synchrotron-powered technology (SR-IMS) as a potential research tool.

To date there is no any study on imaging molecular chemistry and chemical structure of biotech-modified plant tissue on a molecular basis. The objective of this methodology study was to apply a non-invasive and non-destructive synchrotron powered technology - SR-IMS to image molecular chemistry of the modified forage leaf tissue. The infrared molecular vibrational microspectroscopy powered with synchrotron light at Advanced Light Source (ALS, Lawrence Berkeley National Lab, Berkeley, California, Dept. of En...

Xenogeneic bone matrix immune risk assessment using GGTA1 knockout mice.

Homeotransplantation of bones for replacement therapy have been demonstrated reliably in clinical data. However, human donor bones applicable for homeotransplantation are in short supply, which facilitates the search for suitable alternatives, such as xenografts grafts. The α-Gal antigen-related immune risk of xenografts directly affects the safety and effectiveness of the biomaterials and limits their applications in the clinic. The immune risk can be prevented by depletion or breaking anti-Gal antibody p...


Advertisement
Quick Search
Advertisement
Advertisement